WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319513
Description: Pimobendan is a veterinary medication. Pimobendan is both a calcium sensitizer and a selective inhibitor of phosphodiesterase III (PDE3) with positive inotropic and vasodilator effects. Pimobendan is used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve disease (also previously known as endocardiosis), or dilated cardiomyopathy.Research has shown that pimobendan increases survival time and improves quality of life in canine patients with congestive heart failure secondary to mitral valve disease when compared with benazepril, an angiotensin-converting-enzyme (ACE) inhibitor.
MedKoo Cat#: 319513
Chemical Formula: C19H18N4O2
Exact Mass: 334.14298
Molecular Weight: 334.38
Elemental Analysis: C, 68.25; H, 5.43; N, 16.76; O, 9.57
Pimobendan purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 40 g may be 2 weeks.
Synonym: UD-CG115; UD CG115; UD-CG 115; UD-CG-115; Pimobendan; pimobendane. Trade name: Vetmedin and Acardi
IUPAC/Chemical Name: 3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
InChi Key: GLBJJMFZWDBELO-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
SMILES Code: O=C1CC(C)C(C2=CC=C3C(NC(C4=CC=C(OC)C=C4)=N3)=C2)=NN1
The following data is based on the product molecular weight 334.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012 Aug;22(4):398-408. doi: 10.1111/j.1476-4431.2012.00768.x. Review. PubMed PMID: 22928748.
2: Bowles D, Fry D. Pimobendan and its use in treating canine congestive heart failure. Compend Contin Educ Vet. 2011 Nov;33(11):E1. Review. PubMed PMID: 22101450.
3: Boswood A. Current use of pimobendan in canine patients with heart disease. Vet Clin North Am Small Anim Pract. 2010 Jul;40(4):571-80. doi: 10.1016/j.cvsm.2010.04.003. Review. PubMed PMID: 20610012.
4: Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure therapy--a silver bullet? J Am Anim Hosp Assoc. 2006 Mar-Apr;42(2):90-3. Review. PubMed PMID: 16527909.
5: Fuentes VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract. 2004 Sep;34(5):1145-55. Review. PubMed PMID: 15325474.
6: Kubo SH. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology. 1997;88 Suppl 2:21-7. Review. PubMed PMID: 9142432.
7: Fitton A, Brogden RN. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging. 1994 May;4(5):417-41. Review. PubMed PMID: 8043944.
8: Kubo SH. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan. Coron Artery Dis. 1994 Feb;5(2):119-26. Review. PubMed PMID: 8180743.
9: Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J. 1993 Apr;14(4):551-66. Review. PubMed PMID: 8472722.